Core Viewpoint - The company has received FDA approval for its self-developed cancer drug KC1086, marking a significant milestone in its strategic development and potential for future product pipeline expansion in oncology treatment [2]. Group 1: Drug Development - KC1086 is a small molecule inhibitor targeting KAT6, intended for treating advanced recurrent or metastatic solid tumors, with preclinical studies showing over 90% tumor suppression in ER+/HER2 breast cancer models [2]. - The clinical trial for KC1086 is progressing smoothly, having received regulatory approval from the National Medical Products Administration in June 2025 and enrolling its first participant in August 2025 [2][3]. - The company is also advancing other projects, including KC1036 for advanced esophageal squamous cell carcinoma and ZY5301, which is in the registration application phase [3]. Group 2: Financial and Tax Benefits - As of Q3 2025, the company's R&D expenses reached 32.8 million yuan, with a focus on unmet clinical needs in various therapeutic areas [3]. - The company has been re-certified as a high-tech enterprise, allowing it to benefit from a reduced corporate tax rate of 15% for three consecutive years from 2025 to 2027, providing a stable tax environment for R&D investments [4]. Group 3: Investment Outlook - The company is projected to have EPS of 0.88 yuan, 1.11 yuan, and 1.33 yuan for the years 2025 to 2027, with corresponding dynamic P/E ratios of 45.67, 36.09, and 30.16 [5]. - As a leading player in the blood coagulation agent sector, the company is expected to achieve diverse innovation outcomes through ongoing R&D and product introductions, maintaining a buy rating [5].

Investment Rating - The investment rating for the company is "Buy" [5][13] Core Insights - The company has received FDA approval for its self-developed cancer drug KC1086, marking a significant milestone in its innovation capabilities [2][3] - KC1086 is a small molecule inhibitor targeting KAT6, showing promising efficacy in preclinical studies, particularly in ER+/HER2- breast cancer models with a tumor inhibition rate exceeding 90% [2] - The company is actively advancing its R&D pipeline, with a focus on unmet clinical needs in various therapeutic areas, including hemostasis, bone metabolism, oncology, and immunology [3] - The company has been recognized as a high-tech enterprise, allowing it to benefit from favorable tax policies for the next three years [4][9] Financial Summary - As of Q3 2025, the company's R&D expenses reached 32.8 million yuan [3] - The projected revenue for 2025 is 919.53 million yuan, with a growth rate of 11.40% [9][12] - The projected net profit attributable to shareholders for 2025 is 139.26 million yuan, reflecting a significant increase of 229.87% compared to the previous year [9][12] - The company’s total market capitalization is approximately 6.36 billion yuan, with a total share capital of 159.01 million shares [6]